Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

National study on the adequacy of antidotes stocking in Lebanese hospitals providing emergency care

  • Anthony Mansour1,
  • Layla Al-Bizri1,
  • Jad El-Maamary1,
  • Amanda al-Helou1,
  • Rayan Hamade1,
  • Elie Saliba1,
  • Dina Khammash1,
  • Karim Makhoul1,
  • Kamal Matli1,
  • Nada Ghosn2,
  • Mary Deeb1 and
  • Wissam H. Faour1, 3Email author
Contributed equally
BMC Pharmacology and ToxicologyBMC series – open, inclusive and trusted201617:51

DOI: 10.1186/s40360-016-0092-7

Received: 2 August 2016

Accepted: 29 September 2016

Published: 7 November 2016

Abstract

Background

Antidotes stocking is a critical component of hospital care for poisoned patients in emergency. Antidote stocking represents a major health challenge worldwide and in Lebanon. Systematic data monitoring of antidote stocking in Lebanese hospitals is lacking. The objective of this study is to assess the adequacy of antidotes stocking in Lebanese hospitals according to type and quantity and explore the characteristics associated with their differential availability.

Methods

Data collection to assess antidote availability and its correlate was undertaken through a self-administered questionnaire. The questionnaires were distributed by the unit of surveillance at the Ministry of Public Health to eligible hospitals providing emergency care services. The list of essential antidotes was adapted from the World Health Organization (WHO) list and the British Columbia Drug and Poison Information Centre.

Results

Among the 85 Lebanese hospitals surveyed none had in stock all the 35 essential antidotes required. The frequency of stocking by type of antidote varied from a minimum of 1.2 % of the hospitals having a (cyanide kit) to 100 % availability of (atropine and calcium gluconate). Teaching hospitals and those with a large bed-capacity reported a higher number of available antidotes for both immediate and non-immediate use than non-teaching hospitals while controlling for the hospital geographical region and public vs private sector.

Conclusion

The Lebanese hospitals have a suboptimal stock of essential antidotes supply. It is recommended that the Lebanese Ministry of Public Health monitors closely on the hospital premises the adequacy and availability of essential antidotes stock.

Keywords

Antidote stoking Emergency care Lebanese hospitals World health organization

Background

An antidote, as defined by the World Health Organization (WHO), is a therapeutic substance used to counteract the toxic action(s) of a specified xenobiotic [1]. Although emergency supportive care is considered the foundation of toxicological emergency management, unintentional and intentional poisoning continue to be a major contributor to annual mortality rates worldwide [2]. Morbidity, mortality, and the length of hospitalization may be reduced by the appropriate and well-timed use of antidotes [3]. The mainstay in the proper management of a patient in need for an antidote is the immediate administration of the needed antidote and its availability in the hospital emergency. Therefore hospitals and emergency centers should be self-sufficient with regards to antidote stocking. Thus improper stocking or unavailability of the required antidotes are a major factors that lead to mismanagement of poisoned patients.

Data on the availability of antidotes globally is scarce, however recent studies have shown that antidotes are inadequately stocked in many countries and their availability also varies significantly among hospitals within the same country [36]. Accordingly, Dart et al., developed recommendations for antidote stocking and categorizing their availability according to the immediacy of their use in USA [7]. However, these recommendations can be only elaborated when information on antidotes stocking in hospitals providing Emergency care is available. Considering such guidelines are still largely missing in Lebanon, it is therefore recommended to first document antidotes stocking before developing the guidelines [7]. Data also shows that antidote stoking varies by the hospital sector (public or private), bed capacity, presence of particular medical specialists (e.g., emergency care), and number of expected poisoning cases [3, 4]. Lebanon, a country of 4 million inhabitants in the Middle East, has a healthcare system dominated by the private sector, where less than 17 % of its hospitals are administered by the public sector [8]. Lebanese hospitals are usually well equipped with state-of-the art medical equipment in the emergency department, however, antidote availability and stocking are not well monitored. The ministry of health reported an increase in number of hospitalized cases due to poisoning by drugs or toxic substances from 288 cases in 2011 to 336 cases in 2012 [8, 9]. A systematic evaluation of the availability of antidote stocking in Lebanese hospitals has not been undertaken to date. The main objective of this study was to document the availability of antidotes considered essential according to the criteria set by the British Columbia Drug and Poison Information Centre (BC DPIC) and the World Health Organization (WHO) [1].

Methods

Study design

This is a cross sectional survey study that was undertaken among eligible Lebanese hospitals that have an emergency care setting. The data collection period extended from October 2013 to April 2014 by contacting either the emergency unit or pharmacy department in charge of monitoring and providing antidotes in the hospitals. The Lebanese Ministry of Public Health provided us with a list of addresses and contact information of eligible public and private hospitals with emergency care services in Lebanon. The data collection instrument was a self-administered survey that was distributed by the Lebanese Ministry of Public Health, along with a document explaining the objectives and significance of the study. The questionnaire was filed by the person responsible of stocking the antidotes in the emergency unit or hospital pharmacy. The questionnaire included questions on hospitals geographical distribution, working in the public or private sector and type [university (teaching) vs general (non-teaching)] (Additional file 1: Table S4). Also, the hospitals were stratified according to their bed capacity into small (<50 beds), medium (50–150 beds) and large (>150 beds).

Data on the availability of each antidote from a list of 35 antidotes was also collected as well as the reasons when the antidote was not available (adapted from the British Colombia Drug and Poison Information Centre (BCDPIC) and the World Health Organization) [1]. The latter guidelines were used since there are no current specific guidelines for antidotes stocking in Lebanon.

The list of antidotes were also grouped into “immediate” and “non-immediate” as per WHO guidelines. The group of “immediate” are antidotes given within 30 min to one hour and include: Activated Charcoal; Atropine; Calcium Chloride; Calcium Gluconate; D50W; Digoxin F; Ethanol; Flumanezil; Fomepizole; Glucagon; Glucose; Hydroxycobalamin; Methylene Blue; N-acetylcysteine; Naloxone; Pyridoxine; Na bicarbonate; Na nitrate; Na thiosulfate. The group of “non-immediate” antidotes that can be administered after one hour of poisoning are: Cholestyramine; Deferoxamine; Dimercaprol; EDTA; Folic Acid; Insulin; Isoproterenol; Leucovorin; Magnesium; Octreotide; PEG solution; Pralidoximine; Protamine sulfate; Prostigimine; Vitamin K.

Surveys were distributed by the ministry of Public Health surveillance unit to all eligible hospitals in the first week of October 2013. After two months from the initiation of the study a second reminder was sent and those who did not reply were contacted by telephone. By the end of April 2014 all hospitals that did not reply were labeled as non-respondents.

Statistical analysis

Data analysis was done using Statistical Package for Social Sciences (SPSS version 23) software for analysis. The distribution of antidotes by categorical data such as type of hospital was performed by using the chi-square test. The independent sample t–test was used to compare the mean antidotes in the different hospital types, sectors, and location. Additionally, separate multiple regression analysis were also performed in order to explore the hospital characteristics as predictors related to two outcomes number of immediate and non-immediate antidote. Results were considered significant with a p value of less than 0.05.

Results

Table 1 shows the characteristics of the 85 sampled hospitals regarding bed capacity, type, and health sector. More than half of the hospitals had a medium (50–150) bed capacity (57.1 %), and the majority were non-teaching (77.4 %) and privately owned (83.3 %) hospitals. Table 2 describes the availability of antidotes according to antidote type, it ranges from 1.2 % having cyanide kit to 100 % having atropine and calcium gluconate. The number of reported antidotes available in each hospital varies from 5–28 with no hospital having the total 35 antidotes in stock (data not shown).
Table 1

Characteristics of the hospitals in Lebanon that were evaluated during the study

Characteristic

Percentage

Bed capacity

 • Small (<50 beds)

23.8

 • Medium (50–150 beds)

57.1

 • Large (> 150 beds)

16.7

Type of hospital

 • Teaching

77.4

 • Non-teaching

22.6

Sector

 • Public

16.7

 • Private

83.3

Table 2

Prevalence of antidote stocking in Lebanese hospitals

Antidotes

Hospitals

Percent

Atropine

100

Calcium gluconate

100

Glucose

98.8

Insulin

96.4

Sodium bicarbonate

96.4

Magnesium

95.2

Vitamin K

95.2

Naloxone

94.0

Flumazenil

85.7

Protamine sulfate

85.7

NAC

84.5

Prostigmine

83.3

Methylene blue

79.8

Activated charcoal

76.2

Folic acid

67.9

Pralidoxime

63.1

D50W

54.8

Glucagon

52.4

Hydroxycobalamin

44.0

Calcium chloride

44.0

Ethanol

40.5

Octeotride

32.1

PEG solution

41.7

Leucovorin

31.0

Deferoxamine

22.6

Digoxin immune F

21.4

Isoproterenol

20.2

Pyridoxine

19.0

Cholestyramine

6.0

EDTA

6.0

Sodium nitrate

6.0

Fomepizole

3.6

Sodium thiosulfate

3.6

Dimercaprol

2.4

Cyanide Kit

1.2

PEG polyethylene glycol electrolyte, D50W dextrose 50 % in water, NAC N-acetylcysteine, EDTA Ethylenediaminetetraacetic acid

Table 3 shows the reasons reported for not having specific antidotes in stock in the hospitals. The major reason was the availability of the antidote in a nearby hospital followed by alternative medications being used instead. Other reported reasons were: unavailable in the Lebanese market, expensive or available in another location within the hospital.
Table 3

Reasons reported for Not Stocking Antidotes in Lebanese hospitals

Antidote

Percentage

Available in a nearby hospital (N=13)

 Magnesium

100

 Sodium bicarbonate

100

 Vitamin K

100

 Naloxone

75.0

 Protamine sulfate

50.0

 NAC

42.8

 Fomepizole

37.5

 Folic acid

35.7

 Glucagon

35.5

 Pralidoxime

35.0

 Leucovorin

33.3

 Hydroxycobalamin

29.2

 Ethanol

32.1

Alternative can be used (N=8)

 Activated charcoal

61.5

 Calcium chloride

54.2

 D50W

52.3

 Dimercaprol

44.0

 EDTA

40.4

 Prostigmine

33.3

 PEG solution

30.4

 Isoproterenol

30.0

Not available in the market (N=6)

 Cholestyramine

42.3

 Cyanide Kit

36.2

 Digoxin immune F

43.2

 Pyridoxine

39.5

 Sodium nitrate

43.8

 Sodium thiosulfate

39.2

Expensive (N=3)

 Flumazenil

40.0

 Deferoxamine

29.2

 Octeotride

25.7

Available in another place within hospital (N=2)

 Insulin

66.6

 Methylene blue

37.5

PEG polyethylene glycol electrolyte, D50W dextrose 50 % in water, NAC N-acetylcysteine, EDTA Ethylenediaminetetraacetic acid

Distribution of antidotes by hospital geographical location

The hospitals located in Beirut and its suburbs have a slightly higher number of antidotes in stock with a mean of 19.05 ± 5.27 compared to 18.15 ± 4.04 in the other governorates (p = 0.39). The mean number of antidote availability for immediate and non-immediate by geographic location was also not significant (Table 4). Of note, there were significant differences between the region of the hospital and only 5 different antidotes (Additional file 2: Table S1).
Table 4

Analysis of immediate and non-immediate antidotes availability according to hospital type, geographic area and hospital sector

  

N

Mean

Std. deviation

Std. error mean

P-value

Mean number of immediate and non-immediate antidotes availability according to hospital type

Immediate

Non-teaching

65

10.6308

2.69588

0.33438

0.001

Teaching

19

12.4737

1.71167

0.39268

Non-immediate

Non-teaching

65

6.8308

2.13285

0.26455

0

Teaching

19

9.7368

1.75885

0.40351

Analysis of antidote availability according to geographic area (region)

Immediate

Greater Beirut

37

11.1622

2.88207

0.47381

0.315

Others

47

10.9574

2.41335

0.35202

Non-immediate

Greater Beirut

37

7.8919

2.70579

0.44483

0.04

Others

47

7.1702

2.06755

0.30158

Mean number of antidote availability according to hospital sector

Immediate

Private

70

11.1571

2.71141

0.32408

0.394

Public

14

10.5

2.06621

0.55222

Non-immediate

Private

70

7.6714

2.48311

0.29679

0.04

Public

14

6.5714

1.55486

0.41555

Distribution of antidote by type of hospital

Private vs public

The distribution of the antidotes by hospital health sector shows that the mean availability of antidote was 18.84 ± 4.85 in private hospitals versus 17.07 ± 2.79 in public hospitals (p = 0.07), but a significant difference was found between the availability of seven antidotes (Digoxin immune F, Fomepizole, Glucagon, Octeotride, Leucovorin, Isoproterenol, Pyridoxine) and the hospital sector. Furthermore, atropine, calcium gluconate and flumazenil were equally available regardless the hospital sector (Additional file 3: Table S2). The mean number of immediate antidotes available by type of hospital (Private vs Public) did not differ significantly (p-value = 0.315). However, the mean number of 7.7 for non-immediate antidote availability in Private hospitals compared to 6.5 among Public hospitals was significantly different with a p-value = 0.04 (Table 4).

Teaching vs non-Teaching

Additionally, our data showed that teaching hospitals stocked an average of 22.21 ± 3.26 antidotes compared to 17.48 ± 4.41 in non-teaching hospitals (p < 0.0001) and there was a significant difference between the hospital type and nine different antidotes (Additional file 4: Table S3). The mean number of immediate and non-immediate antidote by type of hospital also differed significantly. The mean number in non-teaching hospital for immediate was 10.6 compared to 12.5 among Teaching hospitals. For non-immediate Non-Teaching 6.8 and Teaching 9.7 (Table 4).

Bed capacity

According to the bed capacity the mean availability was 16.90 ± 4.64, 18.48 ± 4.59, and 21.50 ± 3.46 for small, medium and large hospitals respectively (p = 0.014), and a significant difference was found between the hospital size and the availability of seven different antidotes (octeotride, leucovorin, glucagon, pralidoxime, protamine sulfate, naloxone, flumazenil). Moreover, glucose, insulin, atropine, calcium gluconate and sodium bicarbonate were equally available in small and large hospitals (Fig. 1).
Fig. 1

Represents the distribution of the different antidotes among small (24.40 %), medium (58.50 %) and large (17.10 %) hospitals. * p < 0.05 significance different between hospital sizes and each specific antidote

Multiple regression analysis showed that the main predictor of the number of antidote availability is being a teaching compared to non-teaching hospitals (P-value = 0.01) while controlling for hospital sector, geographical area and bed capacity. Multiple regression analysis were also done for immediate and non-immediate antidote separately. Finally, multiple regression analysis showed a similar result as observed for the total number of antidotes where teaching hospitals again seem to have the higher probability of having available both immediate and non-immediate significantly more than non-teaching hospitals (Tables 5, 6 and 7).
Table 5

Regression analysis of the mean antidote availability according to hospital type (teaching vs non-teaching), geographical region and bed capacity

Coefficientsa

Model

Unstandardized coefficients

Standardized coefficients

t

Sig.

B

Std. error

Beta

1

(Constant)

11.239

3.059

 

3.674

.000

Hospital type

4.674

1.315

.429

3.554

.001

Sector

-1.780

1.389

-.137

-1.281

.204

Region

1.294

1.038

.140

1.247

.216

Bed capacity

.856

.848

.119

1.010

.316

aDependent Variable: Mean antidotes

Table 6

Regression analysis of the mean “immediate” antidote availability according to hospital type (teaching vs non-teaching), sector, geographical region and bed capacity region

Coefficientsa

Model

Unstandardized coefficients

Standardized coefficients

t

Sig.

B

Std. error

Beta

1

(Constant)

8.116

1.845

 

4.399

.000

Hospital type

1.970

.793

.319

2.483

.015

Sector

-.970

.838

-.132

-1.158

.250

Region

.670

.626

.128

1.070

.288

Bed capacity

.295

.511

.073

.578

.565

aDependent Variable: Immediate

Table 7

Regression analysis of the mean “not- immediate” antidote availability according to hospital type (teaching vs non-teaching), sector, geographical region and bed capacity region

Coefficientsa

Model

Unstandardized coefficients

Standardized coefficients

t

Sig.

B

Std. error

Beta

1

(Constant)

3.133

1.486

 

2.109

.038

Hospital type

2.715

.639

.488

4.250

.000

Sector

-.791

.675

-.119

-1.171

.245

Region

.599

.504

.127

1.188

.239

Bed capacity

.552

.412

.150

1.339

.184

aDependent Variable: non-immediate

Discussion

The main objective of this study was to evaluate the adequacy of antidote stocking in Lebanese hospitals providing emergency care services. Our results showed that most hospitals had an insufficient number of the main required antidotes which is consistent with other studies from multiple countries [4, 1012]. Hospitals with a larger bed capacity had stocked more antidotes when compared to smaller hospitals and these results were similar to data found by others [6, 10, 1214]. Moreover, we found that the mean number of antidotes that are used either both immediately or non-immediately is significantly different between types of hospitals with teaching hospitals stocked higher number in each category. Such finding is extremely important knowing that most of the teaching hospitals are located in the capital area while hospitals located away from the hospital might lack lifesaving antidotes. The negative impact of lacking important antidotes in areas far from the capital can be minimize since the geographic area of Lebanon is small enough rendering the communication between hospitals an achievable task. In conclusion, antidote stoking of the immediate category needs to be reevaluated particularly in hospitals located outside the capital in order to prevent and reduce the cost of care associated with the lack of such antidotes. Regarding poisoning cases requiring the use of non-immediate antidotes, the health impact of lacking of such antidotes in a particular hospital can be minimized since major hospitals can be reached at reasonable time before irreversible organ damage occurs since the geographic area of Lebanon is relatively small.

Several reasons for not stocking antidotes in smaller hospitals were reported in a recent study in Australia such as budget constraints, perceived lack of antidote need, short expiry dates or the rapid transfer of patients or antidotes [6]. Moreover, inadequate stocking of antidotes in hospitals has also been attributed to the short shelf-life, cost, and lack of awareness about the risks of intoxication. Additionally, hospitals may waive the stocking of antidotes that can be quickly obtained from neighboring institutions in case of an emergency. Finally, one of the key element in the inadequacy of antidotes stocking in the hospital pharmacy is the absence of stocking and management guidelines as well as their implementation [11]. Worthy to note that the number of antidotes among hospitals did significantly differ according to the geographic area emphasizing the role of the LMPH to provide hospitals in far areas with enough medical resources. However, better policies of antidotes stockings are needed to further uncover the needs for particular antidotes in these hospitals. For instance, atropine is available in all hospitals located nearby agriculture areas (usually far from the capital) where the risk of exposure to pesticide poisoning (organophosphates and carbamate poisoning) is high. Of note, pesticide poisoning is becoming a major problem globally and causing thousands of death, it necessitate immediate infusion of the antidote “atropine” along with ventilation support [15, 16]. Hence, the availability of atropine in these hospitals is critical and its availability can limit the catastrophic outcomes associated with delaying treatment.

Cyanide poisoning requires immediate and aggressive treatment and its clinical diagnosis is usually difficult as no specific symptoms are present, whereas laboratory findings require hours to confirm a diagnosis [17]. Therefore, an antidote should be administered when cyanide poisoning is suspected. In Lebanon, the cyanide kit is the least available antidote which raises concern when a case of cyanide poisoning is suspected. Other alternatives approved for empirical therapy in cyanide poisoning include sodium thiosulfate and hydroxycobalamin [18], but they are available in less than 50 % of all hospitals, hence cases of cyanide poisoning cannot be adequately treated. Even though in such incidences the antidotes can be requested from nearby hospitals, the issue of delivery time remains the main concern in Lebanon due to traffic jams or distances between hospitals.

On the other hand, no association has been documented between the hospital sector and the mean availability of antidotes. Subsequently, fomepizole and digoxin immune F, two expensive antidotes used in the treatment of alcohol and digoxin toxicity respectively, were significantly present in public rather than private hospitals highlighting the fact that the public sector funded by the ministry of health had better capabilities of obtaining more expensive antidotes. The number of public hospitals in Lebanon account for 17 % of the total hospitals [8] and the difference of antidote stocking can be attributed to the different poisoning cases encountered and the budget drafted by each of the hospitals sectors. Although, Greater Beirut area has a greater population and more poisoning cases would be expected and managed in this area as compared to the other governorates, an equal distribution of the number of antidotes was documented among all regions in Lebanon and thus there was no centralization among the distribution of antidotes in the capital area and its suburbs. On the other hand, the fact that university hospitals acquired a larger number of antidotes when compared to non-teaching hospitals can be attributed to the higher funding of university hospitals and the variety of clinical exposures needed to be provided to medical students.

Although, this study was relied on antidote lists developed both locally and externally, which may not accurately reflect the coverage required for toxicological emergencies in Lebanon, it may represent an important step toward implementing better antidote stocking policies. Since hospitals didn’t often report the quantity of each antidote they possess so we were unable to determine whether an antidote was stocked in sufficient amount.

Conclusions

This study showed an inadequate antidote stocking in the Lebanese hospitals and that the mean number of antidote available was significantly greater in teaching hospitals vs non-teaching hospitals. Establishing a national antidote database to enhance communication between health institutions regarding their stocks of antidote will lead to a better and effective antidote stocking system. The Lebanese Ministry of Public Health should also review and implement new guidelines regarding stocking of antidotes, taking into consideration the WHO recommendations and the type of toxicological cases in Lebanon.

Abbreviations

BCDPIC: 

British Colombia drug and poison information centre

LMPH: 

Lebanese ministry of public health

WHO: 

World health organization

Declarations

Acknowledgment

Not applicable.

Funding

The entire study was funded by a student grant from the Lebanese American University School of Medicine.

Availability of data and materials

It is not possible to share the raw research data publicly since data privacy could be compromised. However, the raw data are available with the corresponding author, and any researcher interested to gain access to the raw data can address his/her request to the corresponding author at the contact information mentioned in the manuscript. All data generated or analyzed during this study are included in this published article and its supplementary information.

Authors’ contributions

All authors contributed to the generation of the paper. WF contributed in designing, implementation and oversight of the study, and critically prepared, read and agreed on the final format of the submitted paper. AM, LB, JM, AH, RH, ES, DK, KM, KM: participated in data collection, analysis and study implementation; MD: participated in data analysis and critical review of the final manuscript; NG: participated in study design and implementation; and. All the authors read and accepted the final draft of the manuscript.

Authors’ information

Dr Wissam H. Faour is an Assistant Professor of Pharmacology at the Lebanese American University School of Medicine, and has a PhD in Molecular Biology from the University of Montreal and a Post-Doctorate in Cellular and Molecular Medicine from the University of Ottawa (Kidney Research Center). Anthony Mansour, Layla Al Bizri, Jad Maamary, Amanda al Helou, Rayan Hamade, Elie Saliba, Dina Khammash, Karim Makhoul and Kamal Matli are Medical Residents at the Lebanese American University Medical Center- Rizk Hospital. Dr. Mary Deeb is an Associate Professor of Epidemiology and Biostatistics at the Lebanese American University School of Medicine. Dr. Nada Ghosn is Head of the Epidemiological Surveillance Program at the Lebanese Ministry of Public Health.

Competing interest

The authors declare that they have no competing interest.

Consent for publication

Not applicable.

Ethics approval and consent to participate

This study was approved by the Institutional Review Board (IRB) of the Lebanese American University, Tracking number: LAU.SOM.WF1.23/Dec/13.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
School of Medicine, Lebanese American University
(2)
Lebanese Ministry of Public Health
(3)
School of Medicine, Room 4722, Lebanese American University

References

  1. International Program on Chemical Safety., World Health Organization. Guidelines for poison control. Geneva: World Health Organization; 1997.Google Scholar
  2. Watson WA, Litovitz TL, Klein-Schwartz W, Rodgers Jr GC, Youniss J, Reid N, Rouse WG, Rembert RS, Borys D. 2003 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 2004;22(5):335–404.View ArticlePubMedGoogle Scholar
  3. Al-Sohaim SI, Awang R, Zyoud SH, Rashid SM, Hashim S. Evaluate the impact of hospital types on the availability of antidotes for the management of acute toxic exposures and poisonings in Malaysia. Hum Exp Toxicol. 2012;31(3):274–81.View ArticlePubMedGoogle Scholar
  4. Gasco L, Rosbolt MB, Bebarta VS. Insufficient stocking of cyanide antidotes in US hospitals that provide emergency care. J Pharmacol Pharmacother. 2013;4(2):95–102.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Juurlink DN, McGuigan MA, Paton TW, Redelmeier DA. Availability of antidotes at acute care hospitals in Ontario. CMAJ. 2001;165(1):27–30.PubMedPubMed CentralGoogle Scholar
  6. Nissen LM, Wong KH, Jones A, Roberts DM. Availability of antidotes for the treatment of acute poisoning in Queensland public hospitals. Aust J Rural Health. 2010;18(2):78–84.View ArticlePubMedGoogle Scholar
  7. Dart RC, Borron SW, Caravati EM, Cobaugh DJ, Curry SC, Falk JL, Goldfrank L, Gorman SE, Groft S, Heard K, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. Ann Emerg Med. 2009;54(3):386–94. e381.View ArticlePubMedGoogle Scholar
  8. Department of statistics TLMoPH. Statistical Bulletin. 2012.Google Scholar
  9. Department of Statistics MoPH. Statistical Bulletin. 2011.Google Scholar
  10. Dart RC, Stark Y, Fulton B, Koziol-McLain J, Lowenstein SR. Insufficient stocking of poisoning antidotes in hospital pharmacies. JAMA. 1996;276(18):1508–10.View ArticlePubMedGoogle Scholar
  11. Jean-François Bussières BB. Insufficient Stocking of Antidotes in Hospital Pharmacies: Problem, Causes, and Solution. Can J Hosp Pharm. 2000;53.
  12. Ong HC, Yang CC, Deng JF. Inadequate stocking of antidotes in Taiwan: is it a serious problem? J Toxicol Clin Toxicol. 2000;38(1):21–8.View ArticlePubMedGoogle Scholar
  13. Abbott V, Creighton M, Hannam J, Vincent T, Coulter C. Access in New Zealand to antidotes for accidental and intentional drug poisonings. J Prim Health Care. 2012;4(2):100–5.PubMedGoogle Scholar
  14. Higgins MA, Evans R. Antidotes--inappropriate timely availability. Hum Exp Toxicol. 2000;19(9):485–8.View ArticlePubMedGoogle Scholar
  15. Eddleston M, Phillips MR. Self poisoning with pesticides. BMJ. 2004;328(7430):42–4.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Heath AJW MT. Atropine in the management of anticholinesterase poisoning. In: Clinical and experimental toxicology of organophosphates and carbamates. 1992.Google Scholar
  17. Hall AH, Rumack BH. Clinical toxicology of cyanide. Ann Emerg Med. 1986;15(9):1067–74.View ArticlePubMedGoogle Scholar
  18. Sauer SW, Keim ME. Hydroxocobalamin: improved public health readiness for cyanide disasters. Ann Emerg Med. 2001;37(6):635–41.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement